Production of Ac-225 from Th-229 for Targeted α Therapy
Abstract
This work describes a method for the separation and purification of Ac-225 from a Th-229 source. The procedure is based on the combination of ion exchange and extraction chromatographic methods in nitric acid media and allows the preparation of carrier-free, clinical grade Ac-225 with an overall yield exceeding 95%. Quality control of the product is performed using radiometric (alpha, gamma spectrometry) and mass spectrometric methods. The Ac-225 product can be loaded on a radionuclide generator for the preparation of Bi-213 for preclinical and clinical studies of targeted alpha therapy of cancer and infectious diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Joint Research Centre in Karlsruhe, Germany, has produced approximately 13 GBq 225Ac annually since the 1990s.
“The Directorate for Nuclear Safety and Security of the Joint Research Centre (JRC) of the European Commission in Karlsruhe, Germany, the first laboratory to prepare 225Ac/213Bi, has produced approximately 13 GBq 225Ac annually since the 1990s for their center and a wide network of clinical collaborators (89, 90).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [89]
For more than two decades, radiochemical extraction from 229Th, which originated from the decay of the fissile isotope 233U, has been the most utilized strategy for the production of 225Ac and its daughter 213Bi.
“For more than two decades, the radiochemical extraction from 229Th, which is originated from the decay of the fissile isotope 233U (Figure 4), has been the most utilized strategy for the production of 225Ac and its daughter 213Bi (88, 89).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [89]
Cites
Targeted α particle immunotherapy for myeloid leukemia
Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472 · see citing works
Self-citationApostolidis, C., Molinet, R., McGinley, J., Abbas, K., Möllenbeck, J., & Morgenstern, A. (2005) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2004.06.013 · Cited by 176 · see citing works
Self-citationThe feasibility of 225 Ac as a source of ??-particles in radioimmunotherapy
Geerlings, M. W., Kaspersen, F. M., Apostolidis, C., & van der Hout, R. (1993) · Nuclear Medicine Communications · doi:10.1097/00006231-199302000-00009 · Cited by 95 · see citing works
Self-citationDadachova, E., Bryan, R. A., Frenkel, A., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.1004-1006.2004 · Cited by 31 · see citing works
Raman laser spectroscopic studies of bismuth(III) halide complexes in aqueous solutions
Spivakov, B. Y., Stoyanov, E. S., Gribov, L. A., et al. (1979) · Journal of Inorganic and Nuclear Chemistry · doi:10.1016/0022-1902(79)80423-6 · Cited by 30 · see citing works
Magill, J. (2003) · Springer eBooks · doi:10.1007/978-3-642-55764-4 · Cited by 29 · see citing works
Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study
Vandenbulcke, K., Thierens, H., Offner, F. C., et al. (2004) · Nuclear Medicine Communications · doi:10.1097/00006231-200411000-00011 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552 · see citing works
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505 · see citing works
Self-citationMiederer, M., Scheinberg, D. A., & McDevitt, M. R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.009 · Cited by 210 · see citing works
Development of <sup>225</sup>Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180416161908 · Cited by 202 · see citing works
Graf, F., Fahrer, J., Maus, S., Morgenstern, A., Bruchertseifer, F., Venkatachalam, S., Fottner, C., Weber, M. M., Huelsenbeck, J., Schreckenberger, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088239 · Cited by 143 · see citing works
Self-citationSupply and clinical application of Actinium-225 and Bismuth-213.
Morgenstern, A., Apostolidis, C., & Bruchertseifer, F. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.003 · Cited by 141 · see citing works
Bismuth-213 for targeted radionuclide therapy: from atom to bedside.
Ahenkorah, S., Cassells, I., Deroose, C. M., Cardinaels, T., Burgoyne, A. R., Bormans, G., Ooms, M., & Cleeren, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050599 · Cited by 120 · see citing works
An Improved Method for the Production of Ac-225/Bi-213 from Th-229 for Targeted Alpha Therapy.
Zielinska, B., Apostolidis, C., Bruchertseifer, F., & Morgenstern, A. (2007) · Solvent Extraction and Ion Exchange · doi:10.1080/07366290701285108 · Cited by 100 · see citing works
Self-citationShi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
- Authors
- Apostolidis, C., Molinet, R., Rasmussen, G., & Morgenstern, A.
- Affiliations
- Joint Research Centre (DE)
- Venue
- Analytical Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-09-02
- Volume
- 77
- Issue
- 19
- Pages
- 6288-6291
- ISSN
- 0003-2700 (ISSN-L)
- 1520-6882
- OpenAlex
- W2071761375
- Cited by
- 215
- References
- 7
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 20 · 2023: 11 · 2022: 8 · 2021: 13 · 2020: 18 · 2019: 10 · 2018: 20 · 2017: 11 · 2016: 9 · 2015: 6 · 2014: 11 · 2013: 11 · 2012: 10
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Analytical Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Physical Sciences › Chemistry › Inorganic Chemistry › Radioactive element chemistry and processing
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Chemical Reactions and Isotopes
- Keywords
- actinium-225, thorium-229, targeted alpha therapy, radionuclide separation, ion exchange, extraction chromatography, nitric acid medium, carrier-free radionuclides, bismuth-213, radionuclide generator, alpha spectrometry, mass spectrometry, radiopharmaceutical production
- MeSH terms
- Actinium, Anions, Radioisotopes, Thallium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
